Hmmmmm.... From the Information Circular
"Mr. Franzi('s)... most recent experience included serving as the interim global lead for the spin-off of the $4.5 billion Renal Care business (“Vantive”)..... Mr. Franzi also serves as an expert advisor to leading global private equity firms..."
From the Baxter meeting:
"In the kidney care separation we are very advanced in the dual pathway, which is potential sale of the business to a private equity investor but also a spinoff of the business as a publicly traded company."